Get notified when RXRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (worsened) — The company now discloses multiple material weaknesses (plural) versus a single material weakness in the prior period, indicating a broader control deficiency.
- Section 382 Ownership Change (unchanged) — A deemed ownership change occurred on September 25, 2017, which may subject net operating losses and tax credits to annual limitations.
Recursion revenue falls 60.1% to $7.7M, but net loss narrows 23.8% to -$131.0M
Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read
Key Changes
-
high
Total revenue fell 60.1% to $7.7M, driven by completion of certain Roche project phases in the prior period.
MD&A: Revenue verify on EDGAR → -
high
Material weaknesses in internal controls persist and now include multiple weaknesses, including those from the Exscientia integration.
Controls verify on EDGAR → -
high
A Section 382 study concluded a deemed ownership change occurred on September 25, 2017, potentially limiting use of net operating losses and tax credits.
Notes: Tax view on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ESTC 10-Q) is open in full — no account needed.
Partner
Trade RXRX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify